ArticlePLoS neglected tropical diseases2026
Significant gap between Point participation and long‑term treatment adherence: An evaluation of ivermectin MDA in the Kwanware‑Ottou persistent onchocerciasis transmission focus, Wenchi, Ghana.
Article in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite more than 27 years of ivermectin mass drug administration (MDA), onchocerciasis transmission persists in the Kwanware-Ottou focus within the Wenchi Health District of Ghana. This study examined participation in ivermectin MDA over time in this transmission focus.
methodsIn March 2024, two months after MDA using the community-directed treatment with ivermectin (CDTI) approach, settlements within Kwanware-Ottou focus were identified through community consultations and satellite imagery. A census was then conducted integrating an ivermectin treatment coverage evaluation survey (CES) to evaluate community participation in CDTI. Data were cleaned using STATA and analysed in R. Descriptive statistics, multiple logistic regression, and ordinal logistic regression were conducted to examine factors associated with point and effective participation in CDTI. Point participation is the percentage of individuals aged 15 + who took ivermectin during the last CDTI, while effective participation refers to those who have taken it at least ten times in past rounds. Pearson correlation was used to assess the relationship between participation and infection prevalence.
resultsNineteen settlements were identified, with an overall point participation of 80.3% (n = 1461 participants; 95% Confidence Interval, CI:78.6 - 82) for the preceding CDTI. However, 10 settlements had coverage below 80%. Effective participation was only 53.5% (n = 974; CI: 51.2 -55.9), well below the recommended 80%. Participation was influenced by factors such as age, occupation, ethnicity, remoteness, length of stay in the settlement, and mobility (migration). Effective participation was correlated with infection levels, with correlation coefficients of -0.74 for microfilariae prevalence and -0.79 for anti-Ov16 seroprevalence, indicating a strong inverse relationship.
conclusionHigh point participation masks low effective participation and insufficient subdistrict geographical coverage. Conducting exhaustive CES in delineated foci is essential for evaluating CDTI performance, tailoring and strengthening CDTI, and informing alternative strategies to interrupt onchocerciasis transmission. This approach has contributed to effective, context-specific strategies to interrupt transmission in Wenchi and beyond.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.